معرفی
Marcin Imielinski is an Associate Professor in the Department of Pathology at NYU Grossman School of Medicine and a key member of the Perlmutter Cancer Center. He leads the Cancer Genomics Research Program, focusing on advancing the clinical and biological understanding of cancer through whole genome sequencing.
His research centers on genomics, cancer biology, structural DNA variation, and molecular pathology. The Imielinski lab develops innovative computational and experimental methods to analyze complex somatic alterations in cancer genomes. Notably, they have uncovered new classes of mutational processes and structural variants using advanced sequencing technologies like Pore-C for studying 3D genome architecture. Their work has been published in leading journals including Nature, Cell, and Nature Genetics.
The recent publications highlight a strong trend in decoding noncoding and structural genomic changes in cancer, with applications in lung adenocarcinoma, BRCA-deficient cancers, and telomere crisis. These studies integrate algorithm development with deep biological investigation, emphasizing the clinical utility of whole genome analysis.
Marcin Imielinski earned his MD and PhD from the University of Pennsylvania. He completed residency in Pathology at Massachusetts General Hospital and fellowship in Molecular Genetic Pathology at Brigham and Women's Hospital, followed by postdoctoral training at the Broad Institute in the lab of Matthew Meyerson.
- Associate Professor, Department of Pathology, NYU Grossman School of Medicine
- Director, Cancer Genomics Research Program, Perlmutter Cancer Center
While specific awards and grants are not listed in the provided text, his high-impact publications suggest recognition in the field of cancer genomics. He advises a research team focused on developing tools like Chromunity and applying long-read sequencing to understand genome folding in cancer.
His laboratory website is available at mskilab.org.
